Introduction: thirty years ago, the first migraine-specific drugs (triptans) appeared. today two new categories (gepants and ditans) are marketed for acute migraine treatment. that said, is there still a role for conventional therapy? The aim of the present narrative review is to provide an expert overview examining the possible role of the combination paracetamol/caffeine in treatment of acute migraine pain. methods: To understand possible settings for more appropriate use of paracetamol/caffeine (1000 mg/130 mg) in treatment of acute migraine, a structured literature search was performed using the pubmed database by a panel of experts from major Italian headache centers; articles not referring to migraine pain were excluded from this review; review articles were prioritized. results: overall response, even to newer specific and selective trigeminal targeted drugs (TTTs), is not over 60%; thus, there is still room for conventional therapies in acute migraine treatment. the panel identified settings in which the use of paracetamol/caffeine combination to treat acute migraine attacks might offer benefit considering the consolidated use through years, despite the lack of studies directly addressing the efficacy of paracetamol/caffeine in the identified populations: subjects > 65 years of age; presence of cardiovascular (CV) comorbidities; TTTs non-responders; pregnancy and breastfeeding; subjects < 18 years of age; paracetamol/caffeine as add-on therapy. conclusions: paracetamol is included in the world health organization (WHO) essential drug list and has a high level of popularity among patients. caffeine enhances the analgesic effect of other drugs including paracetamol. In early treatment of acute migraine pain, prescribing physicians might consider using the paracetamol/caffeine combination among other options.
Barbanti, P., Allais, G., Cevoli, S., Guerzoni, S., Valeriani, M., Vernieri, F. (2024). The Role of the Combination Paracetamol/Caffeine in Treatment of Acute Migraine Pain: A Narrative Review. PAIN AND THERAPY [10.1007/s40122-024-00581-x].
The Role of the Combination Paracetamol/Caffeine in Treatment of Acute Migraine Pain: A Narrative Review
Valeriani, Massimiliano;
2024-03-06
Abstract
Introduction: thirty years ago, the first migraine-specific drugs (triptans) appeared. today two new categories (gepants and ditans) are marketed for acute migraine treatment. that said, is there still a role for conventional therapy? The aim of the present narrative review is to provide an expert overview examining the possible role of the combination paracetamol/caffeine in treatment of acute migraine pain. methods: To understand possible settings for more appropriate use of paracetamol/caffeine (1000 mg/130 mg) in treatment of acute migraine, a structured literature search was performed using the pubmed database by a panel of experts from major Italian headache centers; articles not referring to migraine pain were excluded from this review; review articles were prioritized. results: overall response, even to newer specific and selective trigeminal targeted drugs (TTTs), is not over 60%; thus, there is still room for conventional therapies in acute migraine treatment. the panel identified settings in which the use of paracetamol/caffeine combination to treat acute migraine attacks might offer benefit considering the consolidated use through years, despite the lack of studies directly addressing the efficacy of paracetamol/caffeine in the identified populations: subjects > 65 years of age; presence of cardiovascular (CV) comorbidities; TTTs non-responders; pregnancy and breastfeeding; subjects < 18 years of age; paracetamol/caffeine as add-on therapy. conclusions: paracetamol is included in the world health organization (WHO) essential drug list and has a high level of popularity among patients. caffeine enhances the analgesic effect of other drugs including paracetamol. In early treatment of acute migraine pain, prescribing physicians might consider using the paracetamol/caffeine combination among other options.| File | Dimensione | Formato | |
|---|---|---|---|
|
s40122-024-00581-x.pdf
solo utenti autorizzati
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
583.71 kB
Formato
Adobe PDF
|
583.71 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


